Clin Rev Allergy Immunol. Clinical Pathway for Early Diagnosis of COVID-19: Updates From Experience to Evidence-Based Practice

[tetano]

Clin Rev Allergy Immunol. 2020 Apr 24.
doi: 10.1007/s12016-020-08792-8. Online ahead of print.
Clinical Pathway for Early Diagnosis of COVID-19: Updates From Experience to Evidence-Based Practice


Guogang Xu ¹ , Yongshi Yang ² , Yingzhen Du ¹ , Fujun Peng ^{3 4} , Peng Hu ¹ , Runsheng Wang ¹ , Ming Yin ¹ , Tianzhi Li ¹ , Lei Tu ⁵ , Jinlyu Sun ⁶ , Taijiao Jiang ^{7 8} , Christopher Chang ^{9 10}



Affiliations

• PMID: 32328954
• DOI: 10.1007/s12016-020-08792-8

Abstract

The COVID-19 pandemic is a significant global event in the history of infectious diseases. The SARS-CoV-2 appears to have originated from bats but is now easily transmissible among humans, primarily through droplet or direct contact. Clinical features of COVID-19 include high fever, cough, and fatigue which may progress to ARDS. Respiratory failure can occur rapidly after this. The primary laboratory findings include lymphopenia and eosinopenia. Elevated D-dimer, procalcitonin, and CRP levels may correlate with disease severity. Imaging findings include ground-glass opacities and patchy consolidation on CT scan. Mortality is higher in patients with hypertension, cardiac disease, diabetes mellitus, cancer, and COPD. Elderly patients are more susceptible to severe disease and death, while children seem to have lower rates of infection and lower mortality. Diagnostic criteria and the identification of persons under investigation have evolved as more data has emerged. However, the approach to diagnosis is still very variable from region to region, country to country, and even among different hospitals in the same city. The importance of a clinical pathway to implement the most effective and relevant diagnostic strategy is of critical importance to establish the control of this virus that is responsible for more and more deaths each day.